The DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index; 79 of the 180 sources its claims cite were checked for support.
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits
Open accessAbstract
The legalization of cannabis for medical and recreational purposes has progressed internationally. Chronic patterns of cannabis use have been associated with disrupted learning, impaired cognitive performance, reduced educational attainment, cannabis use disorder, psychosis/schizophrenia, mood and anxiety disorders, and suicidal behaviors among adolescents and young adults.
Overview
CoChat Summary
TL;DR
This 2024 review summarizes evidence that recreational cannabis use, especially frequent high-THC use, is linked to acute impairment and several longer-term mental and physical health risks, while medical cannabinoid benefits are limited to a few indications. The strongest therapeutic evidence is for CBD in refractory epilepsy, with smaller benefits for spasticity, chronic pain, and chemotherapy-induced nausea/vomiting.
Key findings
- The review states that regular use of high-THC products can produce cannabis use disorder (CUD), and that 22% of people who ever use cannabis meet criteria for CUD, rising to 33% among weekly or daily users.
- Acute consumption of high THC doses can cause time-limited mental, gastrointestinal, and cardiovascular problems and motor vehicle accidents; the paper reports traffic-accident odds ratios ranging from 1.25 to 1.97.
- For psychosis, meta-analyses found a robust association with cannabis use and a dose–response relationship; one multinational study reported that daily use of high-potency cannabis increased psychosis risk fivefold versus non-users, while daily low-potency use doubled risk.
- For medicinal use, the paper says cannabinoids have small beneficial effects for muscle spasticity, limited/inconsistent evidence for chronic pain, higher antiemetic effects than placebo or conventional anti-emetics for CINV, and that CBD is moderately efficacious for refractory epilepsy in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.
Methods
- The paper is a selective literature review intended to update a prior systematic literature search on “benefits and risks of cannabinoids” commissioned by the German Ministry of Health.
- Searches were conducted in PubMed and the Cochrane Central Register of Clinical Trials for 10.5.2016 to 10.5.2023, prioritizing systematic reviews and meta-analyses from the past decade; when unavailable, the authors included strong, adequately powered studies published since the most recent review.
- The references of included studies were screened for additional relevant studies, and the authors used the causal-inference approach outlined in their Text Box 1.
Limitations
- The authors explicitly note that the literature is sparse for some questions, including increased cannabis potency and its effects, and that more rigorous data is needed on outcomes associated with potency, product diversity, and new routes of administration.
- They state that confounding by tobacco and other drug use complicates interpretation of long-term harms, and that case-control and cohort studies are subject to unmeasured confounding.
- Evident from the text: the review is selective rather than a full systematic review of all cannabis evidence, and much of the therapeutic literature is described as limited, heterogeneous, or insufficient for guidance.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
68 Valid · 3 Not valid · 68 Not checked · 39 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Acute cannabis consumption has consistently been associated with a modest increase in the risk of traffic accidents, with odd ratios ranging from 1.25 to 1.97 [17].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Partly supportedcites [17] Preuss UW, Huestis MA, Schneider M et al (2021) Cannabis use and car crashes: a review. Front Psychiatry 12:643315. https://doi.org/10.3389/fpsyt.2021.643315 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says acute cannabis use increases car-crash risk and describes the increase in meta-analytic odds ratios as slight. The Results of Meta-Analyses (page unavailable) report an adjusted OR of 1.25 and an OR of 1.97 for the blood-analysis subgroup, but do not present 1.25–1.97 as the overall range; other reported estimates exceed it. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, there are no reliable cut-off values for blood THC levels that indicate when an individual is impaired.”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Supportedcites [24] Pearlson GD, Stevens MC, D’Souza DC (2021) Cannabis and driving. Front. Psychiatry 12:689444. https://doi.org/10.3389/fpsyt.2021.689444 source
The Discussion (page not provided) says there is no straightforward way to equate blood THC levels with current driving impairment. The Recommendations likewise say that detectable blood THC levels are not a useful standard and that meaningful thresholds lack evidence-based consensus. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Growing evidence indicates that dysregulation of ECS may contribute to brain dysfunction, psychopathology, neurodevelopmental problems, neurodegenerative diseases, neuroinflammation, among other physiological functions [9, 10].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Introduction
What the sources say
- Partly supportedcites [9] Lu HC, Mackie K (2016) An introduction to the endogenous cannabinoid system. Biol Psychiatry 79(7):516–525. https://doi.org/10.1016/j.biopsych.2015.07.028 sourceExperimental — accuracy not yet measured
The Introduction links ECS perturbations to psychiatric disorders, and the LTD section suggests that disrupted cannabinoid signaling could contribute to developmental abnormalities. The Endocannabinoid degradation section links loss of an enzyme involved in endocannabinoid metabolism to a neurodegenerative syndrome. The Cannabinoid receptors section describes changes in CB2 expression during inflammation, but does not establish that ECS dysregulation contributes to neuroinflammation. Page numbers were not available in our copy. (LLM, conf=0.84)
- Partly supportedcites [10] Lowe H, Toyang N, Steele B, Bryant J, Ngwa W (2021) The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci 22(17):9472. https://doi.org/10.3390/ijms22179472 sourceExperimental — accuracy not yet measured
The Introduction (§1.1; page unavailable) links the ECS to nervous function, neurogenesis, pre- and post-natal development, and neuropsychological and neurodegenerative diseases. The Neurological/Neurodegenerative Diseases section (§3; page unavailable) also implicates the ECS in neurological pathology and describes cannabinoid modulation of neuroinflammation. The paper does not establish that ECS dysregulation contributes to every listed outcome, particularly neurodevelopmental problems or neuroinflammation. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Research is showing that there are some individuals who use cannabis to reduce symptoms of mood or anxiety disorders [40].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Supportedcites [40] Beletsky A, Liu C, Lochte B, Samuel N, Grant I (2024) Cannabis and anxiety: a critical review. Med Cannabis Cannabinoids 7(1):19–30. https://doi.org/10.1159/000534855 source
The Introduction’s table reports that people with lifetime depression used cannabis for self-medication and that some chronic users reported anxiety-related symptom relief. It also states that cannabis is used by some chronic users seeking to alleviate anxiety. This supports the claim about why some individuals use it, without establishing that it effectively treats those disorders. (LLM, conf=0.91)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There is partial support from longitudinal studies for a causal link between cannabis use and a reduction in motivation, that has been referred to as an “a motivation syndrome” [31].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Supportedcites [31] Pacheco-Colón I, Limia JM, Gonzalez R (2018) Nonacute effects of cannabis use on motivation and reward sensitivity in humans: a systematic review. Psychol Addict Behav 32(5):497–507. https://doi.org/10.1037/adb0000380 source
The Discussion concludes that two longitudinal studies provide evidence of a causal relationship between cannabis use and reduced motivation and reward sensitivity. It also describes the broader evidence for an “amotivational syndrome” as equivocal, consistent with the citing sentence’s qualified wording. (LLM, conf=0.94)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
124 more claims · 46 with their cited sources checked
Create a free account to see all 178 claims and to verify the 4 references still open.
- It may state two separate claims as one. 40
- Probably not a substantial claim. 13
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
(2012) · SpringerReference · doi:10.1007/springerreference_121117 · Cited by 20,570
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
(2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/103.1437-1588 · Cited by 11,796
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
International Statistical Classification of Diseases and Related Health Problems
(2011) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-0-387-79948-3_3055 · Cited by 4,151
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169 · cited 4×
“Mild to moderate central nervous or gastro-intestinal side effects are more common with cannabinoids than with placebo but severe side effects are rare [13].”
InfluentialNeurobiologic advances from the brain disease model of addiction
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1511480 · Cited by 2,008 · cited 1×
“Case–control neuroimaging studies of the brain with high-resolution provide early evidence for altered brain integrity in brain regions with a high density of CB1 receptors in heavy cannabis users [75].”
Self-citationDegenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A., Whiteford, H., Leung, J., Naghavi, M., Griswold, M., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30337-7 · Cited by 1,572 · cited 1×
“Worldwide, 22 million people are estimated to meet criteria for CUD, similar in number to opioid use disorders (27 million people) [56].”
Self-citationInternational statistical classification of diseases and related health problems. Tenth revision.
Brämer, G. R. (1988) · PubMed · Cited by 1,492
Groce, E. (2018) · Journal of Medical Regulation · doi:10.30770/2572-1852-104.4.32 · Cited by 1,330
Research works printed but not linked: 1
- Hoch E, Friemel C, Schneider M (2019) Cannabis: benefits and risks. Springer, Heidelberg
Cited by
The adverse public health effects of non-medical cannabis legalisation in Canada and the USA
Mekonen, T., Hoch, E., Fischer, B., Dawson, D., & Hall, W. (2025) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00299-8 · Cited by 49
Self-citationWilson, J., Dobson, O., Langcake, A., Mishra, P., Bryant, Z., Leung, J., Dawson, D., Graham, M., Teesson, M., Freeman, T. P., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00015-5 · Cited by 48
“However, few reviews included evidence for the treatment of all mental disorders and SUDs as the primary indication, 10,11 conducted metaanalyses, 11,14 critically evaluated the risk of bias and quality of evidence, 13,14 or examined the evidence according to the type of cannabinoid.”
Self-citationRamer, R., & Hinz, B. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108851 · Cited by 18
Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges
Sič, A., George, C., Gonzalez, D. F., Tseriotis, V., & Knežević, N. N. (2025) · Neurology International · doi:10.3390/neurolint17090141 · Cited by 16
“Rates of dizziness reach 25%, drowsiness 8%, and disorientation 4%, with up to 12% of patients discontinuing treatment due to side effects [76,77].”
Acute cannabis intoxication among the paediatric population
Malta, G., Albano, G. D., Lavanco, G., Brancato, A., Cannizzaro, C., Argo, A., Contorno, S., Plescia, F., & Zerbo, S. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1558721 · Cited by 19
Metadata
- Authors
- Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W.
- Affiliations
- LMU Klinikum (DE)
- National Institute on Alcohol Abuse and Alcoholism (US)
- IFT Institut für Therapieforschung (DE)
- Australian Catholic University (AU)
- University of Bath (GB)
- The University of Queensland (AU)
- Corresponding author
- Hoch, E.
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2024-09-19
- Volume
- 275
- Issue
- 2
- Pages
- 281-292
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- PMC
- PMC11910417
- OpenAlex
- W4402698048
- Semantic Scholar
- 04009c33b5339cffb27ec4198594652c85a4294d
- Cited by
- 139
- References
- 119
- Citations by year
- 2026: 86 · 2025: 52 · 2024: 1
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
- Funders
- Klinikum der Universität München
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- cannabis, cannabinoids, delta-9-tetrahydrocannabinol, recreational cannabis use, medical cannabis, cannabis use disorder, adolescent cannabis use, psychosis, schizophrenia, cognitive impairment, prenatal cannabis exposure, cannabidiol, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, cannabis legalization
- MeSH terms
- Cannabinoids, Cannabis, Marijuana Abuse, Humans, Dronabinol, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. https://app.cochat.ai/papers/10.1007/s00406-024-01880-2
- The paper
- Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01880-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.